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Abstract 
Background: Achieving good glycemic control in intensive care units (ICU) requires a safe and efficient insulin infu-
sion protocol (IIP). We aimed to compare the clinical performance of two IIPs (Leuven versus modified Yale protocol) 
in patients admitted to medical ICU, by using continuous glucose monitoring (CGM). This is a pooled data analysis of 
two published prospective randomized controlled trials. CGM monitoring was performed in 57 MICU patients (age 
64 ± 12 years, APACHE-II score 28 ± 7, non-diabetic/diabetic: 36/21). The main outcome measures were percentage 
of time in normoglycemia (80–110 mg/dl) and in hypoglycemia (<60 mg/dl), and glycemic variability (standard devia-
tion, coefficient of variation, mean amplitude of glucose excursions, mean of daily differences).
Results: Twenty-two subjects were treated using the Leuven protocol and 35 by the Yale protocol; >63,000 CGM 
measurements were available. The percentage of time in normoglycemia (80–110 mg/dl) was higher (37 ± 15 vs. 
26 ± 11%, p = 0.001) and percentage of time spent in hypoglycemia was lower (0[0–2] vs. 5[1–8]%, p = 0.001) in 
the Yale group. Median glycemia did not differ between groups (118[108–128] vs. 128[106–154] mg/dl). Glycemic 
variability was less pronounced in the Yale group (median SD 28[21–37] vs. 47[31–71] mg/dl, p = 0.001; CV 23[19–31] 
vs. 36[26–50]%, p = 0.001; MODD 35[26–41] vs. 60[33–94] mg/dl, p = 0.001). However, logistic regression could not 
identify type of IIP, diabetes status, age, BMI, or APACHE-II score as independent parameters for strict glucose control.
Conclusions: The Yale protocol provided better average glycemia, more time spent in normoglycemia, less time in 
hypoglycemia, and less glycemic variability than the Leuven protocol, but was not independently associated with 
strict glycemic control.
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Background
Consensus exists that overt hyperglycemia (>150  mg/
dl) in patients admitted to the intensive care unit (ICU) 
should be treated to improve morbidity and survival 
[1]. However, there is little agreement on the ideal tar-
get range of glycemia [2]. Strict glycemic control (80–
110  mg/dl) is no longer recommended for most ICUs, 
but in highly standardized ICUs a strict target may be 
feasible without increasing hypoglycemia. Achieving 
strict glycemic control is a complex task since during 
ICU stay severity of illness and degree of insulin resist-
ance may fluctuate, nutritional delivery may change, and 
interventions (e.g., administration of corticosteroids) may 
produce frequent changes in insulin needs [2]. Therefore, 
multiple insulin infusion protocols (IIPs) were created, all 
meant to balance efficacy with safety (avoid hypoglyce-
mia), and attainability (nursing workload).
So far, no single IIP has been established as the most 
effective for obtaining tight glycemic control. Earlier 
observational studies and randomized controlled trials 
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(RCTs) in medical ICU (MICU) or mixed ICU settings, 
and targeting a glycemia between 80 and 110  mg/dl, 
reported that 22–60% of all blood glucose values were in 
target for paper-based IIPs [3–14], compared to 42–69% 
for computerized decision-supported algorithms [4, 10, 
11, 14, 15]. The efficacy and safety of different IIPs on 
glycemic control have recently been investigated using 
computer simulation models [16, 17] and in RCTs in 
cardiac surgery patients [18, 19]. However, to the best 
of our knowledge, comparing the effect of different IIPs 
on glucose control has never been investigated in MICU 
patients. With this pooled data analysis of two published 
prospective RCTs [5, 6], we assessed the clinical perfor-
mance of two IIPs (Leuven versus modified Yale protocol) 
in patients admitted to MICU, by means of continuous 
glucose monitoring (CGM), allowing a complete picture 
of glucometrics.
Methods
This is a pooled data analysis of two prospective RCTs 
conducted at the medical ICUs of the Antwerp Univer-
sity Hospital (45 beds, including 14 MICU beds) and 
Middelheim Hospital, a university-affiliated tertiary 
care center (36 beds, including 13 MICU beds) [5, 6]. 
Patients were recruited between 04/2004 and 03/2005 
for the first study and between 07/2007 and 09/2009 for 
the second study. Both MICUs applied the same stand-
ards of care, with a nurse-to-patient ratio between 1:2.5 
and 1:3.0. Each patient or the closest family member 
gave written informed consent. Patients were included if 
they were between 18 and 75 years, treated by IV insu-
lin, and expected to stay in MICU for ≥3 days. Patients 
were not enrolled if pregnant, if surgery was the reason 
for admission, or if a do not reanimate code was pre-
sent. The studies were approved by the ethics commit-
tees of both hospitals (Middelheim approval no. 2345 and 
UZA 6/43/211) and conducted in accordance with the 
amended Declaration of Helsinki.
Severity of illness was scored using the Acute Physiol-
ogy And Chronic Health Evaluation II (APACHE-II) and 
the Sequential Organ Failure Assessment (SOFA) score 
[20, 21]. The neurologic score was zero when patients 
were sedated. Enteral nutrition was started as soon as 
possible, at 25 kcal/kg body weight per day.
Glucose monitoring
Forty-eight-hour CGM was initiated within the first 
48  h after admission using a microdialysis-based device 
that is not equipped with alarms (GlucoDay® in the first 
study and GlucoDay®S in the second study, A. Menar-
ini Diagnostics, Florence, Italy). The methodology has 
been described before [5, 6]. Briefly, a microdialysis fiber 
(Medica, Medolla, Italy) was inserted subcutaneously 
into the periumbilical region using an 18-gauge Tef-
lon® (DuPont, Wilmington, DE) catheter as a guide. The 
device does not use any coagulant. The device uses a glu-
cose oxidase-based amperometric biosensor to measure 
glucose concentrations in the interstitial dialysate every 
3 min over a 48 h period.
Data analysis for accuracy and glucometrics was 
performed by applying, in silico to the CGM signal, a 
two-point calibration according to the manufacturer’s 
requirements (one calibration every 24 h). This was per-
formed in order to avoid an overestimation of the sys-
tem’s accuracy if one uses a higher number of calibration 
points. In the RT-CGM group, however, to be as safe as 
possible and to account for possible changes in subcu-
taneous glucose recovery due to hemodynamic altera-
tions (e.g., hypotension, shock, vasoactive drugs), for 
each sensor, a six-point calibration was performed (after 
2, 6, 12, 18, 24, and 36  h) using arterial BG values, but 
these data were not used for statistical analysis [6]. This 
was done to assure that the glucose readings and trends 
shown by RT-CGM would be clinically reliable. At pre-
sent, RT-CGM is becoming more common practice, but 
at the time of the study, a real-time CGM device was not 
approved to make clinical adjustments of insulin therapy, 
and our ethical committee would not approve clinical 
decisions to be made solely on the basis of RT-CGM at 
that time. In order to avoid clinical decisions being made 
on potentially inaccurate CGM data, nurses had to take 
an additional arterial blood glucose sample. Thus, direct 
corroboration of the data was explicitly needed. The RT-
CGM system was thus used only as a prompt to take 
an extra blood glucose sample if the rate of change in 
glucose exceeded 25  mg/dl per 30  min. Since no differ-
ences in glucometrics were observed in the REGIMEN 
trial between in patients randomized to RT-CGM ver-
sus blinded CGM, we pooled the data. For all patients, 
adjustments of insulin therapy were made on the basis of 
arterial blood glucose values [6].
Insulin infusion protocols
Twenty-two patients received continuous IV insulin 
(regular insulin Actrapid; Novo Nordisk, Bagsvaerd, 
Denmark) according to the Leuven protocol, target-
ing a blood glucose between 80 and 110  mg/dl [5, 13]. 
Thirty-five subjects were treated with IV insulin (insulin 
aspart, Novo Nordisk, Bagsvaerd, Denmark) according to 
a modified Yale protocol, targeting a blood glucose level 
between 80 and 120 mg/dl [6].
In both groups, arterial blood glucose levels were 
measured using an on-site blood gas analyzer (Rapidlab® 
1265, Siemens, München, Germany) and they were used 
to adjust the insulin infusion rate. Insulin in a concen-
tration of 50 units in 50 cc 0.9% NaCl was infused using 
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the Injectomat Agilia® syringe infusion system (flow rate 
change: range 0.1–200  ml/h, Fresenius Kabi, Bad Hom-
burg, Germany). In both groups, the arterial blood glu-
cose sampling interval varied between 1 and 4  h. For 
more details on the insulin infusion protocols, the reader 
is referred to the original publications [5, 6].
Outcome parameters
The percentage of time spent in the target range of glyce-
mia (80–110 mg/dl) was the primary outcome parameter. 
Secondary outcome variables were percentages of time 
spent in hypoglycemia (<60  mg/dl), in hyperglycemia 
(>150 and >200 mg/dl), and parameters of glycemic fluc-
tuations (SD: standard deviation [22], CV: coefficient of 
variation [22], MAGE: mean amplitude of glucose excur-
sions [23], CONGA: continuous overlapping net glycemic 
action [24], and MODD: mean of daily differences [25]. 
We also calculated the low blood glucose index (LBGI) 
and the high blood glucose index (HBGI) as measures 
of risk of hypo- and hyperglycemia [26]. All glucometric 
data reported are those calculated using CGM data. A 
CGM reading <60 mg/dl, confirmed by an arterial blood 
glucose sample <60  mg/dl, lasting for >6  min (6  min 
being the time of two CGM measurements) was defined 
as a hypoglycemic event. We rigorously followed the rec-
ommendations on measurement of blood glucose and 
reporting glycemic control in critically ill adults [27].
Statistical analysis
Results were analyzed using SPSS (SPSS Inc., Chicago, 
USA). Distributions of continuous data were tested for 
normality by Kolmogorov–Smirnov test. The unpaired 
t test or Mann–Whitney U test were used to determine 
differences between groups, with Bonferroni adjust-
ments for multiple comparisons. Data are expressed as 
mean  ±  SD or median [25th–75th percentile]. Differ-
ences in distributions of categorical data were evaluated 
by χ2 or Fisher’s exact test. Stepwise forward logistic or 
linear regression analysis was performed to assess the 
strength and independency of associations. A two-tailed 
p < 0.05 was considered significant.
Results
Over 63,000 CGM data points were analyzed from 57 
adults (men/women: 30/27, non-diabetic/diabetic: 36/21) 
admitted to the MICU. Mean age was 64 ± 12 years. They 
were severely ill as demonstrated by a mean APACHE-II 
score of 28 ± 7 and SOFA score of 10 ± 4. Table 1 shows 
reasons for admission and interventions used.
Comparison of Leuven versus Yale protocol
Twenty-two subjects were treated using the Leuven pro-
tocol and 35 by the Yale protocol. The distribution of 
diabetic subjects differed between groups (13/22 Leu-
ven vs. 8/35 Yale; p = 0.0016). Patients in the Yale group 
tended to be older. Reasons for admission were compara-
ble between groups with exception of neurologic disease/
coma. Feeding habits were different in the two groups 
(p  =  0.003) with enteral feeding being less frequently 
used in the Leuven group (3/22 vs. 20/35). The APACHE-
II score was similar, whereas the SOFA score tended to be 
higher in the Yale group.
Patients in the Leuven group required much more 
IV insulin compared to those treated by the Yale pro-
tocol (Table  1). Despite a similar number of arterial 
blood glucose measurements, patients in the Yale pro-
tocol had better glucometrics with a higher percentage 
of time in target glycemia (80–110  mg/dl) (37 ±  15 vs. 
26  ±  11%, p  =  0.001) and a lower percentage of time 
spent in hypoglycemia (0[0–2] vs. 5[1–8]%, p =  0.001). 
Also percentage of time spent between 60 and 150 mg/dl 
(81 ± 7 vs. 66 ± 24%, p < 0.0001), 80–125 mg/dl (57 ± 18 
vs. 36  ±  21%, p  <  0.0001), between 80 and 145  mg/
dl (74  ±  17 vs. 48  ±  23, p  <  0.0001), and between 70 
and 180  mg/dl (91 ±  10 vs. 69 ±  19%, p  <  0.0001) was 
higher in the Yale group. Figure  1 shows the time-in-
band for the different ranges of targets for both groups. 
Median glycemia, however, did not differ between groups 
(118[108–128] (log: 114[105–125]) vs. 128[106–154] 
(log: 122[99–136]) mg/dl) (Table  1). Glycemic variabil-
ity was less pronounced with the use of the Yale pro-
tocol (median[IQR] SD 28[21–37] vs. 47[31–71] mg/
dl, p  =  0.001; median CV 23[19–31] vs. 36[26–50]%, 
p = 0.001; median MODD 35[26–41] vs. 60[33–94] mg/
dl, p  =  0.001). Significant better LBGI and HBGI were 
observed in the Yale group (Table  1). Eight insulin/glu-
cose plots comparing non-diabetic and diabetic patients 
treated according to the Leuven protocol versus accord-
ing to the modified Yale protocol are shown in Fig. 2, pro-
viding the reader with a good visual image.
Characteristics of subjects achieving strict 
versus above‑target glycemic control
Subjects achieving strict glycemic control (n  =  19), 
defined as having an average glycemia ≤110  mg/dl, did 
not differ with regard to gender, diabetic status, age, 
BMI, reason for admission, severity of illness, and inter-
ventions used as compared to the ones not obtaining an 
average glycemia ≤110 mg/dl, with the exception of the 
use of glucocorticoids (p = 0.001) (Table 2). The distribu-
tion according to insulin infusion protocol used (Leuven 
vs. Yale) also did not differ between groups. Insulin doses 
infused and a number of arterial blood glucose measure-
ments were similar as well. Most glucometrics (% of time 
within target) including glycemic variability (SD, MODD, 
LBGI and HBGI) were better in the group achieving 
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Table 1 Baseline characteristics, interventions used and glucometrics of patients treated by the Leuven versus Yale pro-
tocol
Total cohort Leuven Yale Statistics
Number of patients 57 22 35 p value
Patient demographics
 Men/women 30/27 13/9 17/18 NS
 Diabetic status (no/type1/type2) 36/6/15 9/4/9 27/2/6 0.0016
 Age (years) 64 ± 12 60 ± 13 66 ± 10 0.055
 BMI (kg/m2) 26.8 ± 5.4 27.5 ± 7.1 26.3 ± 4.0 NS
Admission reason
 Septic shock 22 13 9 NS
 Neurologic disease/coma 9 0 9 0.004
 Cardiopulmonary resuscitation 9 1 8 NS
 Respiratory failure 6 1 5 NS
 Cardiogenic shock 7 3 4 NS
 Other 4 4 0 NS
Severity of illness
APACHE-II score 28 ± 7 27 ± 7 28 ± 7 NS
SOFA score 10 ± 4 9 ± 4 11 ± 3 0.072
Clinical interventions
 Mechanical ventilation 44 16 28 NS
 Vasopressor therapy 35 14 21 NS
 Inotropic therapy 20 6 14 NS
 Hemodialysis 14 9 5 NS
 No/total parenteral/enteral feeding 17/17/23 9/10/3 8/7/20 0.003
 Glucocorticoids 27 12 15 NS
 Blood transfusion 15 4 11 NS
 Antibiotics 46 19 27 NS
Outcome parameters
 LOS in ICU (days) 15 ± 9 11 ± 6 17 ± 10 0.019
 In hospital mortality 20 7 11 NS
Insulin dose
 Day 1 (units) 138 (48–190) 50 (27–80) 0.001
 Day 2 (units) 116 (54–116) 56 (28–81) 0.006
Glucose parameters
 HbA1c (%) 6.3 (5.8–7.0) 6.0 (5.7–6.6) NS
 HbA1c (mmol/mol) 45 (40–53) 42 (39–49) NS
 Median glycemia (mg/dl) 128 (106–154) 118 (108–128) NS
 % of time at glycemia
  <60 mg/dl 5 (1–8) 0 (0–2) 0.001
  80–110 mg/dl 26 ± 11 37 ± 15 0.001
  >150 mg/dl 29 ± 23 17 ± 13 <0.0001
  >200 mg/dl 13 ± 19 3 ± 5 <0.0001
  60–150 mg/dl 66 ± 24 81 ± 7 <0.0001
  70–180 mg/dl 69 ± 19 91 ± 10 <0.0001
 Nr of art blood glc measurements/day 10 ± 2 10 ± 4 NS
 Glucose variability parameters
  SD (mg/dl) 47 (31–71) 28 (21–37) 0.001
  Coefficient of variation (%) 36 (26–50) 23 (19–31) 0.001
  IQR 66 (47–82) 37 (27–43) <0.0001
  MAGE (mg/dl) 73 (47–128) 52 (37–83) 0.061 (NS)
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strict glycemic control. Logistic regression analysis could 
not identify type of IIP, diabetes status, age, BMI, or 
APACHE-II score as independent parameters for strict 
glucose control. The only parameter which showed an 
independent association with strict glucose control was 
the administration of glucocorticoids (p = 0.001).
Characteristics of diabetic versus non‑diabetic subjects
No differences in patient demographics except for BMI 
(p  =  0.02), in reason for admission, severity of illness, 
and clinical interventions used, were present between 
diabetic (n =  21) and non-diabetic critically ill patients 
(Table 3). There were more diabetic patients in the Leu-
ven protocol (p = 0.009). Diabetic subjects required more 
insulin, had a worse median glycemia (131[110–166] vs. 
116[107–128] mg/dl, p = 0.034), spent less time in target 
glycemia (25 ± 12 vs. 36 ± 15%, p = 0.006), more time 
in hypoglycemia (4[1–10] vs. 0[0–1]%, p  =  0.001) than 
non-diabetic subjects. All other glucometrics, including 
glycemic variability parameters, were worse as well in 
diabetic patients (see Table 3).
In the non-diabetic group, patients in the Yale protocol 
spent more time in target glycemia (40 ± 15 vs. 25 ± 10%, 
p  =  0.009), less time in hypoglycemia (0[0–0] vs. 1[0–
6]%, p  =  0.013), and glycemic variability tended to be 
smaller (SD p = 0.076, CV p = 0.057, MODD p = 0.021) 
than those treated by the Leuven protocol. Median glyce-
mia was similar (117[108–127] vs. 115[101–140]) in both 
groups (Additional file 1: Table S1). In the diabetic sub-
jects, insulin needs were lower (p = 0.044) and patients 
spent less time at a glycemia >150  mg/dl (26  ±  21 vs. 
35 ± 25%, p = 0.003) in the Yale compared to the Leu-
ven group. However, median glycemia (120[108–140] vs. 
136[111–169] mg/dl), time spent in hypoglycemia or at 
target range, and parameters of glycemic variability were 
similar between groups (Additional file 1: Table S1).
Discussion
Achieving strict glycemic control without risk of hypo-
glycemia in the ICU is difficult. It requires a compre-
hensive and safe insulin infusion protocol (IIP) that is 
both detailed enough and practical enough to be easily 
implemented by ICU nurses [2, 28]. Multiple IIPs have 
been developed, but to the best of our knowledge this is 
the first study comparing the clinical efficacy (% time in 
target glycemia) and safety (hypoglycemia, glycemic vari-
ability) of two IIPs in MICU patients by means of CGM. 
Overall, compared to existing data (see Table  4, [3–15, 
29–38], both our IIPs were able to obtain reasonably 
strict glucose control without excessive risk of hypogly-
cemia. The percentage of time in normoglycemia was 
higher (37 vs. 26%), and percentage of time in hypogly-
cemia lower (0 vs. 5%) and glycemic variability was less 
pronounced in patients treated with the Yale IIP. Diabe-
tes status can, however, be a confounding factor [34]. We 
Table 1 continued
Total cohort Leuven Yale Statistics
  MODD (mg/dl) 60 (33–94) 35 (26–41) 0.001
  M-100 10 (4–25) 4 (2–5) <0.0001
  CONGA1 (mg/dl) 20 (14–39) 15 (13–24) NS
  CONGA2 (mg/dl) 30 (22–53) 23 (18–34) 0.036
  CONGA4 (mg/dl) 38 (28–66) 29 (20–43) 0.012
  LBGI 2.6 (1.0–3.7) 0.7 (0.4–1.4) 0.011
  HBGI 2.5 (1.0–8.0) 1.3 (0.5–1.8) 0.018
  Glucose variability 42 (29–67) 28 (20–34) 0.001
Data are presented as numbers, as mean ± SD or median (25–75th percentile)























Target Range (mg/dL) 
Leuven
Yale
Fig. 1 Average percentage time in range and SD over the groups 
(Yale vs. Leuven) for the different glycemia target ranges. P < 0.0001 
for all three ranges
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observed an imbalance in the number of diabetic subjects 
with more diabetic patients in the Leuven group. Diabetic 
as compared to non-diabetic subjects required more 
insulin, had worse glycemic control, and larger glycemic 
variability, thereby possibly blunting the effect of the IIP. 
However, logistic regression could not identify type of 
IIP, diabetes status, or severity of illness as independent 
parameters associated with strict glucose control. When 
comparing Yale versus Leuven protocol in non-diabetic 
subjects, patients in the Yale protocol had better glu-
cometrics. This was evident, despite the low number of 
patients. In the diabetic subgroup, however, the advan-
tages of the Yale protocol were less pronounced.
Up till now no single IIP has been established as the 
most effective for obtaining tight glycemic control 
[28, 39, 40]. The IIP should be tailored to the subset of 
patients being treated and to local resources, because 
an excellent validated IIP is no guarantee for optimal 
glucose control unless it is carefully implemented. Most 
IIPs show significant similarities, but differences relate to 
target glucose levels (80–110  mg/dl versus ranges vary-
ing between 90 and 180  mg/dl), initial glycemic thresh-
old (>150–200 mg/dl), infusion rates, use of boluses, and 
frequency of monitoring. Changes in insulin infusion rate 
may relate to actual glycemia, direction and/or veloc-
ity of change in glycemia, degree of insulin resistance, 
and insulin dose. The population treated (surgical vs. 
medical ICU, diabetes status) may also affect the perfor-
mance of the IIP [2, 28, 39, 40]. The competence of the 
nurses and clarity of instructions also influence outcome. 
Fig. 2 Insulin glucose plots comparing 4 non-diabetic and 4 diabetic patients treated according to the Leuven protocol versus according to the 
modified Yale protocol. CGM continuous glucose monitoring
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Table 2 Baseline characteristics, interventions used and  glucometrics of  patients reaching an average glycemia 
≤110 mg/dl versus those with an average glycemia >110 mg/dl
Data are presented as numbers, as mean ± SD or median (25–75th percentile)
LOS in ICU length of stay in ICU, IQR interquartile range, MAGE mean amplitude of glycemic excursions, MODD mean of daily differences, LBGI low blood glucose index, 
HBGI high BGI
Avg glyc ≤ 110 mg/dl Avg glyc >110 mg/dl Statistics
Number of patients 19 38
Patient demographics
 Men/women 8/11 22/16 NS
 Diabetic status (no/type1/type2) 14/1/4 23/4/11 NS
 Age (years) 65 ± 11 63 ± 12 NS
 BMI (kg/m2) 26.3 ± 3.8 27.1 ± 6.1 NS
Severity of illness
 APACHE-II score 27 ± 6 28 ± 7 NS
 SOFA score 10 ± 4 10 ± 3 NS
Clinical interventions
 Mechanical ventilation 14 31 NS
 Vasopressor therapy 12 23 NS
 Hemodialysis 5 9 NS
 No/total parenteral/enteral feeding 4/6/9 13/11/14 NS
 Glucocorticoids 15 12 0.01
 Antibiotics 17 29 NS
Protocol (Leuven/Yale) 7/12 15/23 NS
Insulin dose
 Day 1 (units) 62 (33–133) 63 (39–128) NS
 Day 2 (units) 67 (23–101) 70 (42–120) NS
Glucose parameters
 HbA1c (%) 6.1 (5.6–6.7) 6.0 (5.8–6.9) NS
 HbA1c (mmol/mol) 43 (38–50) 70 (42–120) NS
 Median glycemia (mg/dl) 104 (100–108) 128 (119–141) <0.0001
 % of time at glycemia
  <60 mg/dl 5 (0–8) 0 (0–4) 0.067
  80–110 mg/dl 41 ± 14 27 ± 13 0.001
  >150 mg/dl 6 ± 6 28 ± 18 <0.0001
  >200 mg/dl 1 ± 2 10 ± 16 0.017
  60–150 mg/dl 89 ± 11 69 ± 19 <0.0001
  70–180 mg/dl 86 ± 14 80 ± 19 NS
 Nr of art blood glc measurements/day 10 ± 3 10 ± 4 NS
 Glucose variability parameters
  SD (mg/dl) 25 (20–36) 38 (29–63) 0.003
  Coefficient of variation (%) 25 (20–33) 29 (23–44) NS
  IQR 33 (27–55) 45 (35–76) 0.031
  MAGE (mg/dl) 50 (34–72) 60 (43–100) 0.085
  MODD (mg/dl) 29 (22–45) 42 (32–76) 0.005
  M-100 2 (1–4) 6 (4–14) 0.001
  CONGA1 (mg/dl) 15 (12–19) 21 (15–35) 0.008
  CONGA2 (mg/dl) 22 (17–28) 32 (20–48) 0.010
  CONGA4 (mg/dl) 29 (18–43) 42 (27–69) 0.011
  LBGI 2.7 (0.9–3.8) 0.7 (0.2–1.9) 0.001
  HBGI 0.3 (0.2–1.1) 2.0 (1.4–4.5) <0.0001
  Glucose variability 21 (17–28) 36 (29–53) <0.0001
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Computerized decision-supported algorithms might pro-
vide superior glucose control compared to paper-based 
IIPs because of reduced errors by enabling the use of 
complex mathematical calculations and better protocol 
consistency. In MICUs and mixed ICUs where a glyce-
mia between 80 and 110 mg/dl was targeted, 22–60% of 
all blood glucose values were reported to be in target for 
paper-based IIPs [3–14], compared to a higher percent-
age (42–69%) for computerized IIPs [4, 10, 11, 14, 15] 
(Additional file 1: Digital Content–Table S1). In contrast, 
in a before–after study in 192 surgical ICU patients, Bar-
letta et al. [29] could not observe significant glucometric 
differences between the computer-assisted versus paper-
based IIP. It is probably not the paper or computer that 
makes the largest difference; but the IIP algorithm itself 
and the competence of the staff.
A head-to-head comparison of different IIPs on glyce-
mic control has only been performed in RCTs in cardiac 
surgery. Blaha et  al. [18] compared two paper protocols 
with a computerized IIP in 120 patients, showing that the 
computerized IIP provided better average glucose con-
trol, but with a longer time in hypoglycemia risk range 
than the paper protocols. Dumont and Bourguignon [19] 
compared the effect of a computerized (EndoTool) ver-
sus a paper IIP (modified Portland protocol) in 300 ICU 
patients, showing better glucose control and nurses’ sat-
isfaction with the EndoTool IIP. In both studies, however, 
it was not only the protocol that differed but also the way 
it was implemented (paper vs. computerized), making it 
difficult to assess the true value of the protocol itself.
Measurement frequency is an inherent part of an IIP 
and will affect glucometrics. Recently, the effect of the IIP 
(Yale vs. University of Washington), frequency of glucose 
measurements (hourly vs. every 5  min), and measure-
ment imprecision on glycemic control efficacy was stud-
ied using a simulation model [16]. In both IIPs, the rates 
of hypo- and hyperglycemia and of glycemic variability 
increased with increasing measurement imprecision. Oth-
ers investigated the performance of the IIP versus meth-
odology of glucose measurements (blood glucose meter 
vs. CGM) at different levels of measurement accuracy 
[17]. The protocol itself proved to have a greater effect on 
glycemic control efficacy than the glucose measurement 
method, with the Yale protocol showing the best perfor-
mance. However, hypoglycemia risk was lower in CGM-
informed IIPs [17]. Thus, efficacy of the IIP together with 
performance and accuracy of the CGM device used both 
contribute to the success of tight glucose control. In the 
future, validated computerized IIPs can be guided by real-
time CGM in a semi-closed loop, thereby improving effi-
cacy, safety and reducing nursing workload.
Comparison of glucometrics between studies using dif-
ferent IIPs is difficult due to differences in population, 
Table 3 Baseline characteristics, interventions used 
and glucometrics of non-diabetic versus diabetic patients
Data are presented as numbers, as mean ± SD or median (25–75th percentile)
LOS in ICU length of stay in ICU, IQR interquartile range, MAGE mean amplitude 
of glycemic excursions, MODD mean of daily differences, LBGI low blood glucose 
index, HBGI high BGI
Non‑DM DM Statistics
Number of patients 36 21
Patient demographics
 Men/women 19/17 11/10 NS
 Age (years) 65 ± 11 62 ± 12 NS
 BMI (kg/m2) 26 ± 4 29 ± 7 0.02
Severity of illness
 APACHE-II score 29 ± 6 26 ± 7 NS
 SOFA score 11 ± 4 9 ± 3 NS (0.064)
Clinical interventions
 Mechanical ventilation 27 17 NS
 Vasopressor therapy 23 12 NS
 Hemodialysis 12 2 NS (0.06)
 No/total parenteral/enteral 
feeding
7/13/16 10/4/7 NS (0.075)
 Glucocorticoids 20 7 NS
 Antibiotics 30 16 NS
Protocol (Leuven/Yale) 9/27 13/8 0.009
Insulin dose
 Day 1 (units) 48 (26–82) 127 (51–175) 0.001
 Day 2 (units) 46 (25–85) 113 (67–168) 0.009
Glucose parameters
 HbA1c (%) 5.9 (5.6–6.3) 6.9 (6.1–7.3) <0.0001
 HbA1c (mmol/mol) 41 (38–45) 52 (43–56) <0.0001
 Median glycemia (mg/dl) 116 (107–128) 131 (110–166) 0.034
 % of time at glycemia
  <60 mg/dl 0 (0–1) 4 (1–10) 0.001
  80–110 mg/dl 36 ± 15 25 ± 12 0.006
  >150 mg/dl 32 ± 15 24 ± 11 0.001
  >200 mg/dl 3 ± 15 15 ± 20 0.001
  60–150 mg/dl 83 ± 12 63 ± 23 <0.0001
  70–180 mg/dl 90 ± 11 69 ± 19 <0.0001
 Nr of art blood glc  
measurements/day
10 ± 4 10 ± 3 NS
 Glucose variability  
parameters
  SD (mg/dl) 28 (21–35) 53 (40–75) <0.0001
  Coefficient of variation (%) 23 (19–30) 38 (29–51) <0.0001
  IQR 38 (28–45) 66 (41–108) <0.0001
  MAGE (mg/dl) 49 (35–66) 87 (56–127) 0.002
  MODD (mg/dl) 35 (26–42) 59 (35–116) <0.0001
  M-100 4 (2–5) 12 (6–29) <0.0001
  CONGA1 (mg/dl) 15 (13–20) 30 (19–41) <0.0001
  CONGA2 (mg/dl) 22 (17–30) 44 (26–59) <0.0001
  CONGA4 (mg/dl) 30 (21–43) 60 (37–86) <0.0001
  LBGI 0.7 (0.3–1.8) 2.3 (0.9–3.7) 0.013
  HBGI 1.2 (0.4–1.8) 3.0 (1.4–10.3) 0.002
  Glucose variability 28 (20–34) 44 (34–79) <0.0001
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Table 4 Summary of several insulin infusion protocols in different ICU settings
Authors ICU type Study n % Diabetic 
patients




Goldberg et al. 
(2004)
MICU Observational 52 56 Yale 100–139 Hospital glucose 
meter: near hourly 
measurements
Van den Berghe 
et al. (2006)
MICU RCT 1200 17 Paper: Leuven 80–110 ABG: q1-4 h
Kulnik et al. (2008) MICU Observational 10 20 eMPC (computer) 80–110 Variable sampling 
rate: q20 min-4 h
Shetty et al. (2012) MICU Observational 90 66 Yale 120–160 POC meter: hourly 
measurements
Holzinger et al. 
(2010)
MICU RCT 124 19 Leuven 80–110 CGM
De Block et al. 
(2015)
MICU RCT 35 23 Yale 80–110 CGM
Finney et al. (2003) Mixed Observational 523 16 Paper 90–145 ABG
Juneja et al. (2007) Mixed Observational 2398 NR Clarian Gluco 
Stabilizer
80–110 POC: q1-2 h
Chase et al. (2008) Mixed Observational 371 17 SPRINT 80–110 Sampling rate: 
q1-2 h
Morris et al. (2008) Mixed Before–after 755 NR eProtocol-insulin 
versus paper
80–110 POC: q1-4 h
Preiser et al. GLU-
CONTROL (2009)
Mixed RCT 1078 21 Paper: glucontrol 80–110 POC: q1-4 h
NICE SUGAR (2009) Mixed RCT 6104 20 Paper: Leuven 81–108 ABG
Marvin et al. (2013) Mixed Retrospective 1657 NR Computerized Yale 100–140 POC: variable time 
interval
Van Herpe et al. 
(2013)
Mixed RCT 300 21 LOGIC-insulin 
computerized
80–110 ABG: variable time 
interval: q1-4 h
Krinsley et al. (2015) Mixed Retrospective 3297 23 Paper: Stamford 70–140 POC: q3 h
Vogelzang et al. 
(2005)
SICU Observational 179 15 GRIP 72–135 POC blood gas ana-
lyzer: variable
Plank et al. (2006) SICU: cardiotho-
racic surgery
RCT 60 23 eMPC versus paper 80–110 POC: variable sam-
pling rate: q1 h-4 h




RCT 60 45 eMPC 80–110 Variable sampling 
rate: q1 h-4 h
Saager et al. (2008) SICU: cardiotho-
racic ICU




Dortch et al. (2008) SICU: trauma ICU RCT 552 Computer versus 
paper
80–110 POC q1-4 h
Blaha et al. (2009) SICU: cardiac 
surgery
RCT 120 14 eMPC versus paper 
(Matias versus 
Bath)
80–110 ABG: protocol 
dependent: q1-4 h
Barletta et al. (2011) SICU Before–after 192 28 Computer versus 
paper
80–110 POC: variable 
sampling rate: 
q30 min-2 h versus 
q2 h

































Goldberg et al. 
(2004)
61 h Percent of hourly 
BG values in 
target range




Van den Berghe 
et al. (2006)
NR Mean morning 
BG
NA 111 ± 29 versus 
153 ± 31
% of patients: glc 
<40 mg/dl: 18.7 
versus 3.1%
NA [13]
Kulnik et al. 
(2008)
72 h Percent of BG 
values in target
47 ± 13% 109 ± 13 % data at glc 
<40 mg/dl: 0%
NA [15]
Shetty et al. 
(2012)
59 h Percent of BG 
values in target 
range




Holzinger et al. 
(2010)
72 h CGM data: per-
cent of data in 
target range
59 ± 20 versus 
55 ± 18
106 ± 18 versus 
111 ± 10
Rate: 1.9% versus 
11.5%
NA [9]
De Block et al. 
(2015)
96 h CGM data: per-
cent of data in 
target range
37 ± 12 versus 
34 ± 10
119 ± 17 versus 
122 ± 11
% of time at glc 
<60 mg/dl: 








Finney et al. 
(2003)
22–89 h Time spent in 
glucose band 
80–110 mg/dl
4 (0–20)% NR 0 ± 1% NA [31]
Juneja et al. 
(2007)
NR Percent of data in 
target range
52 versus 32% 107 ± 39 % data at glc 
<50 mg/dl: 0.4 
versus 0.5%
NA [10]
Chase et al. 
(2008)
53 h Percent of BG 
values in target
54% 108 ± 27 % of data at glc 
<72 mg/dl: 
3.8%
SD: 27 mg/dl [4]
Morris et al. 
(2008)
4–22 days Percent of BG 
values in target
42 versus 28% 116 versus 134 % data at glc 
<40 mg/dl: 11.1 
versus 5.1%
NA [11]






time of BG val-
ues in range
43% 117 (IQR: 108–
130) mg/dl
Proportion of 
time at glc 
<40 mg/dl: 
5.9 ± 27%







NR 115 ± 18 versus 
144 ± 23
% of patients: glc 
<40 mg/dl: 6.8 
versus 0.5%
NA [7]
Marvin et al. 
(2013)
NR Percent of hourly 
BG values in 
target range
92% 124 % of data 
40–70 mg/
dl: 1.1% and 
in 17.6% of 
patients
NA [34]
Van Herpe et al. 
(2013)
26–113 h Percent of BG 
values in target 
range
69 ± 17 versus 
60 ± 19
106 ± 9 versus 
107 ± 11
% data at glc 
<60 mg/dl: 0.6 
versus 1.2%
Max change in 




Krinsley et al. 
(2015)
36–120 h Percent of time 
of BG values in 
target range
Non-DM versus 








% of patients: 
glc <70 mg/dl: 
non-DM versus 
DM: 18 versus 
31%
CV: non-DM 
versus DM: 18 
versus 27%
[33]
Vogelzang et al. 
(2005)
1.6 (0.8–4.7) days Percent of time 
of BG values in 
target
78 (66–88)% 121 (108–135) % of patients: glc 
<40: 0.6%; glc 
<63: 11.2%
NA [38]
























Plank et al. (2006) 48 h Percent of time in 
target range








over 48 h: 0 
versus 2
NA [35]
Hovorka et al. 
(2007)
24 h Percent of time in 
target range
60 ± 23 versus 
28 ± 16
112 ± 20 versus 
130 ± 20
% of data at glc 
<52 mg/dl: 0% 
versus 0%
NA [32]
Saager et al. 
(2008)
9 h Percent of BG 
values in target
84 versus 60% 126 ± 18 versus 
147 ± 27
Episodes of hypo 
(<60 mg/dl) 
during ICU: 4 
versus 1
NA [36]
Dortch et al. 
(2008)
NR Percent of BG 
values in target
42 versus 34% 116 ± 37 versus 
120 ± 37
% data at glc 
<40 mg/dl: 0.2 
versus 0.5%
NA [30]
Blaha et al. (2009) 45–48 h Time in target 
range
46 ± 3 versus 
38 ± 3 versus 
40 ± 3%
106 ± 4 versus 
121 ± 4 versus 
117 ± 4
Time in hypo 
(<52 mg/dl): 
0 ± 0 versus 
0.4 ± 0.2 versus 
0.4 ± 0.3%
NA [18]
Barletta et al. 
(2011)
67 versus 98 h Percent of BG 
values in target
49 ± 14 versus 
40 ± 12
113 ± 11 versus 
116 ± 11
% data at glc 
<40 mg/dl: 2.1 
versus 4.1%
SD: 25 ± 9 versus 
31 ± 11 mg/dl
[29]
Dumont et al. 
(2012)
NA Percent of BG 
values in target 
range
70 ± 15 versus 
62 ± 18
138 ± 16 versus 
141 ± 20
Number of hypo 
events <60 mg/
dl: 7 (5%) versus 
18 (11%)
SD:36 ± 18 ver-
sus 42 ± 21
[19]
target glycemia, and frequency of glucose monitoring. 
In addition, many different glucometrics are reported 
in different studies, including metrics of central ten-
dency (mean or median glycemia, time-averaged glu-
cose, admission glycemia, proportion of glucose values in 
target), metrics of extremes (percentages or episodes of 
hypo- or hyperglycemia), and metrics of dispersion (SD, 
coefficient of variation, MAGE). The robustness of gluco-
metrics depends largely on the number of measurements 
per time unit used for its calculation. Accurate assess-
ment of time in target glycemia, or in hypo- or hyper-
glycemia, and of glucose variability can only be done by 
using validated CGM methodology.
Our study has some limitations and strengths. This is a 
pooled data analysis of two prospective RCTs conducted 
at the medical ICUs, using relatively old data. Indeed, 
patients were recruited between 04/2004 and 03/2005 
for the first study and between 07/2007 and 09/2009 for 
the second study. However, pooling the CGM data is 
justifiable in our opinion because the same CGM sen-
sor was used in both studies and the study population 
and standards of care in both services were comparable. 
However, our results might not be applicable to a mixed 
or surgical ICU setting. Despite more than 63,000 CGM 
glucose measurements being available for analysis, due to 
the small number of patients and heterogeneity of groups, 
statistical superiority of the Yale protocol could not be 
proven.
A major strength, in our opinion, when comparing 
IIPs, is the use of CGM data which provides a complete 
picture of glucometrics. We did not make use of study 
nurses particularly focused on glucose control, but imple-
mented our study in a routine clinical setting, allowing a 
more clinically relevant picture.
In summary, the use of a safe and efficient IIP is a pre-
requisite to correctly implement strict glycemic targets. 
Both IIPs have proven to balance efficacy with safety (avoid 
hypoglycemia and glycemic variability) and attainability 
(nursing workload). Overall, the modified Yale protocol 
provided better glucose control with more time spent in 
normoglycemia, less time spent in hypoglycemia, and less 
glycemic variability as compared to the Leuven protocol.
MICU medical intensive care unit, SICU surgical ICU, RCT randomized controlled trial, NR not reported, NA not assessed, ABG arterial blood glucose, POC point of care, 
SD standard deviation
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